How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

45,641 results for

Obesity Medication

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Clinical Appropriateness Guidelines: Radiation Oncology Brachytherapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatment guidelines

for medical necessity review , due to billing practices or claims that are not consistent with other providers in terms of frequency or some other manner. CPT ® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT ® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data (...) radiotherapy for prostate cancer based on pre-treatment portal imaging. Wong has also reported that using computed tomography based IGRT, shifts of greater than 10 mm were needed 21.2% of the time to correctly position the prostate in moderately to severely obese patients (BMI >35). This was significantly more than shifts needed in normal weight, overweight and mildly obese patients. ASTRO has used this scenario as an example of where IGRT may be required in conjunction with three-dimensional conformal

2018 AIM Specialty Health

162. Benefit of Delayed Fertility Therapy With Preconception Weight Loss Over Immediate Therapy in Obese Women With PCOS. Full Text available with Trip Pro

Benefit of Delayed Fertility Therapy With Preconception Weight Loss Over Immediate Therapy in Obese Women With PCOS. In overweight/obese women with polycystic ovary syndrome (PCOS), the relative benefit of delaying infertility treatment to lose weight vs seeking immediate treatment is unknown.We compared the results of two, multicenter, concurrent clinical trials treating infertility in women with PCOS.This was a secondary analysis of two randomized trials conducted at academic health centers (...) studying women 18-40 years of age who were overweight/obese and infertile with PCOS.We compared immediate treatment with clomiphene from the Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial (N = 187) to delayed treatment with clomiphene after preconception treatment with continuous oral contraceptives, lifestyle modification (Lifestyle: including caloric restriction, antiobesity medication, behavioral modification, and exercise) or the combination of both (combined) from the Treatment

2017 The Journal of clinical endocrinology and metabolism Controlled trial quality: predicted high

163. Letter to the Editor: Vagal Blocking (vBloc) Therapy; A New Era of Clinical Therapy for Extreme Obesity Full Text available with Trip Pro

Letter to the Editor: Vagal Blocking (vBloc) Therapy; A New Era of Clinical Therapy for Extreme Obesity 27933506 2018 05 07 2018 12 02 1708-0428 27 2 2017 02 Obesity surgery Obes Surg Letter to the Editor: Vagal Blocking (vBloc) Therapy: a New Era of Clinical Therapy for Extreme Obesity : Re: Apovian et al. Two-Year Outcomes of Vagal Nerve Blocking (vBloc) for the Treatment of Obesity in the ReCharge Trial. Obesity Surgery. 2016. 483-484 10.1007/s11695-016-2484-6 Boi Shannon K SK University (...) Research Support, N.I.H., Extramural Comment United States Obes Surg 9106714 0960-8923 IM Obes Surg. 2017 Jan;27(1):169-176 27506803 Bariatric Surgery Humans Obesity Obesity, Morbid Vagus Nerve All authors have no commercial associations that might be a conflict of interest in relation to this article. 2016 12 10 6 0 2018 5 8 6 0 2016 12 10 6 0 ppublish 27933506 10.1007/s11695-016-2484-6 10.1007/s11695-016-2484-6 PMC5239744 NIHMS835421 Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1244-59 22695735

2017 Obesity Surgery

164. The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy Full Text available with Trip Pro

The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy Weight management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration (...) has approved two intragastric balloons and aspiration therapy for the treatment of obesity: Apollo Orbera is indicated for the treatment of Class I and Class II obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35-55 kg/m2. These devices have proven safe and effective in clinical trials and are gaining commercial acceptance in the USA; the Orbera has been used

2017 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

165. Continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a systematic review and meta-analysis of randomised controlled trials

Continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a systematic review and meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears (...) research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures

2019 PROSPERO

166. Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents Full Text available with Trip Pro

Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents Obesity and its related metabolic disorders are serious health problems worldwide, and lead to various health-related complications, including cancer. Among human cancers, hepatocellular carcinoma (HCC) is one of the most common malignancies affected by obesity. Therefore, obesity and its related disorders might be a key target for the prevention of HCC. Recently, new research indicates (...) , a pharmaceutical agent, reduced the incidence of HCC in obese and diabetic mice, and was also associated with improvements in insulin resistance and chronic inflammation. In this article, we review the detailed molecular mechanisms that link obesity to the development of HCC in obese individuals. We also summarize recent evidence from experimental and clinical studies using either nutraceutical or pharmaceutical agents, and suggest that nutraceutical and pharmaceutical approaches targeting metabolic

2016 World Journal of Gastroenterology

167. The Patient Centred Medical Home: barriers and enablers to implementation

The Patient Centred Medical Home: barriers and enablers to implementation The Patient Centred Medical Home: barriers and enablers to implementation An Evidence Check rapid review brokered by the Sax Institute for COORDINARE. January 2018 An Evidence Check rapid review brokered by the Sax Institute for COORDINARE. January 2018. This report was prepared by: Jim Pearse and Deniza Mazevska – Health Policy Analysis Pty Ltd. January 2018 © Sax Institute 2018 This work is copyright. It may (...) : Pearse J, Mazevska D. The Patient Centered Medical Home: barriers and enablers: an Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for COORDINARE, 2018. Disclaimer: This Evidence Check Review was produced using the Evidence Check methodology in response to specific questions from the commissioning agency. It is not necessarily a comprehensive review of all literature relating to the topic area. It was current at the time of production (but not necessarily

2018 Sax Institute Evidence Check

168. Geographic Availability of Physicians Certified by the American Board of Obesity Medicine Relative to Obesity Prevalence. (Abstract)

Geographic Availability of Physicians Certified by the American Board of Obesity Medicine Relative to Obesity Prevalence. The objective of this study is to determine the distribution of adult and pediatric American Board of Obesity Medicine (ABOM) diplomates relative to the prevalence of obesity by US state.Data from the ABOM physician directory were used to determine original specialty and US state. Physicians were labeled as "adult medicine" physicians (i.e., internal medicine, family (...) medicine, or internal medicine and pediatrics), "pediatric medicine" physicians (i.e., pediatrics, family medicine, or internal medicine and pediatrics), and "other physicians" (i.e., surgical specialty, other specialty, or unknown). Prevalence of obesity by state, according to the Centers for Disease Control and Prevention, was used for adults and adolescents in 2017 and for children in 2014. Counts of ABOM-certified adult medicine physicians and pediatric medicine physicians were conducted relative

2019 Obesity

169. Heterogeneity in Response to Treatment of Adolescents with Severe Obesity: The Need for Precision Obesity Medicine. Full Text available with Trip Pro

Heterogeneity in Response to Treatment of Adolescents with Severe Obesity: The Need for Precision Obesity Medicine. Treating pediatric severe obesity is challenging because of the complex biological, behavioral, and environmental factors that underpin the disease. The multifactorial etiology of obesity combined with the physiologic complexity of the energy regulatory system contributes to treatment variability. The goal of this secondary analysis of pooled data was to describe the degree (...) variability in response will be vital for advancing precision medicine approaches to address obesity.© 2019 The Obesity Society.

2019 Obesity

170. Study on health hazards through medicines purchased on the Internet: a cross-sectional investigation of the quality of anti-obesity medicines containing crude drugs as active ingredients. Full Text available with Trip Pro

Study on health hazards through medicines purchased on the Internet: a cross-sectional investigation of the quality of anti-obesity medicines containing crude drugs as active ingredients. Weight-loss medicines, including crude drugs and herbal supplements disguised as diet-aid products, are readily obtainable and distributed widely, especially in Southeast Asia. Even if such products are unapproved or prescription-only medicines, consumers can purchase them through an agency or directly (...) and not medicines. Even though we did not analyze the constituents of all crude drugs, we found some active ingredients in the items. Sibutramine was detected in items confirmed to be supplements, including those containing Poria sclerotium and Ophiopogonis tuber. Each capsule contained ≈ 12 mg of sibutramine, which is the daily dose for anti-obesity medicines. Sibutramine is not approved for use in Japan and its sale has been suspended in Europe and the USA owing to serious adverse effects on the circulatory

2015 BMC Complementary and Alternative Medicine

171. Effect of BAriatric Surgery Versus Optimal Medical Therapy on Cardiovascular Health and Atherosclerosis in Obese, Type II Diabetic Patients

Effect of BAriatric Surgery Versus Optimal Medical Therapy on Cardiovascular Health and Atherosclerosis in Obese, Type II Diabetic Patients Effect of BAriatric Surgery Versus Optimal Medical Therapy on Cardiovascular Health and Atherosclerosis in Obese, Type II Diabetic Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect of BAriatric Surgery Versus Optimal Medical Therapy on Cardiovascular Health and Atherosclerosis in Obese, Type II Diabetic Patients (BASTA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov

2015 Clinical Trials

172. A pilot study exploring the efficacy and safety of herbal medicine on Korean obese women with metabolic syndrome risk factors: Double blinded, randomized, multicenter, placebo controlled study protocol clinical trial. Full Text available with Trip Pro

A pilot study exploring the efficacy and safety of herbal medicine on Korean obese women with metabolic syndrome risk factors: Double blinded, randomized, multicenter, placebo controlled study protocol clinical trial. Obesity is associated with metabolic syndrome, a condition that increases one's risk for heart disease and other conditions. The prevalence of obesity and associated diseases have steadily increased among Korean adults. The effect of the herbal medicines Daesiho-tang (DSHT (...) ) and Chowiseungcheng-tang (CST) on obesity have been reported. The purpose of this study is to evaluate the efficacy and safety of Daesiho-tang and Chowiseungcheng-tang on obese Korean women with high risk for metabolic syndrome.This study is a randomized, double-blinded, placebo-controlled, multi-center, 3-arm, parallel group clinical trial. A total of 120 participants will be enrolled and randomly assigned to the Daesiho-tang group, the Chowiseungcheng-tang group, or the placebo group in a 1:1:1 ratio using

2020 Medicine

173. Centrally-acting drugs for obesity cause more harm than good

Centrally-acting drugs for obesity cause more harm than good Centrally-acting drugs for obesity cause more harm than good | BMJ EBM Spotlight by Centrally acting medicines increase the chance of losing at least 5% of body weight, but their use increases the risks of serious of harms Igho Onakpoya Are the benefits and harms of currently available centrally-acting weight loss drugs (medicines that act on the brain) different from those withdrawn from the market at the time of approval? Well (...) , not really. And the methods used to assess benefits and harms of medicines with similar mechanisms of action require improvements. We assessed the benefits and harms of centrally acting weight loss medicines using data from (i.e., the trials drug manufacturers used as evidence to gain marketing licenses). We also compared the benefits and harms of currently approved medicines with those that have been withdrawn from the market after approval because of concerns over harms. In total, we included five

2018 Evidence-Based Medicine blog

174. Psychoactive Drugs & Obesity

Psychoactive Drugs & Obesity Psychoactive Drugs & Obesity - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Psychoactive Drugs & Obesity March 14, 2018 Is using psychoactive drugs to treat obesity a good idea? Igho Onakpoya Would you be willing to lose about 5% of your body weight, but at same time increase your risk of experiencing nervous or psychiatric disorders? It’s a choice you may have to make (...) if you decide to take some weight loss drugs. To better understand this we conducted a systematic review where we evaluated the benefits and harms of anti-obesity medicines that act through higher centres (the brain) ( ). We included pivotal trials (these were the trials that drug manufacturers used to gain approval to market the medicines) that compared the medicines with dummies. In total, we included five different medicines – there were 16 trials with a total of 24,555 participants. Two

2018 CEBM blog

175. Quantifying sociodemographic and income disparities in medical therapy and lifestyle among symptomatic patients with suspected coronary artery disease: a cross-sectional study in North America. Full Text available with Trip Pro

Quantifying sociodemographic and income disparities in medical therapy and lifestyle among symptomatic patients with suspected coronary artery disease: a cross-sectional study in North America. To evaluate potential gaps in preventive medical therapy and healthy lifestyle practices among symptomatic patients with suspected coronary artery disease (CAD) seeing primary care physicians and cardiologists and how gaps vary by sociodemographic characteristics and baseline cardiovascular risk.Cross (...) , smoking or being obese.Preventive treatment gaps affected 14% of patients with hypertension, 36% of patients with dyslipidaemia and 32% of patients with diabetes. Overall, 49% of patients were sedentary, 18% currently smoked and 48% were obese. Women were significantly more likely to not take a statin for dyslipidaemia and to be sedentary. Patients with lower socioeconomic status were also significantly more likely to not take a statin. Compared with Whites, Blacks were significantly more likely

2017 BMJ open

176. Atomic force microscopy for biomechanical and structural analysis of human dermis: a complementary tool for medical diagnosis and therapy monitoring. (Abstract)

Atomic force microscopy for biomechanical and structural analysis of human dermis: a complementary tool for medical diagnosis and therapy monitoring. Skin mechanical properties are usually measured considering the entire skin thickness and very little is known about the mechanical behaviour of individual skin layers. We propose atomic force microscopy (AFM) as a tool to quantify nanoscale changes in the biomechanical properties and ultrastructure of human papillary dermis exposed to different (...) and present a larger D-period than those in the control sample. Our results open the possibility to use structural and mechanical analysis based on AFM as a complementary tool for medical diagnosis and therapy monitoring.© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

2017 Experimental Dermatology

177. Unanticipated Nocturnal Oxygen Requirement during Positive Pressure Therapy for Sleep Apnea and Medical Comorbidities Full Text available with Trip Pro

. Conceivably, in such patients, home-based management of SDB may not detect or therefore adequately treat persistent hypoxia.In this retrospective study of 200 patients undergoing laboratory-based polysomnography, we ascertained significant medical comorbidities (chronic obstructive pulmonary disease, congestive heart failure, and morbid obesity) and their association with the need for unanticipated O2 supplementation to PAP therapy. Postural oxygen (SpO2) desaturations between upright and reclining (...) were associated with unanticipated need for nocturnal O2 supplementation. A clinical prediction rule of less than two determinants (age older than 50 y, morbid obesity, chronic obstructive pulmonary disease, and postural SpO2 desaturation greater than 5%) had excellent negative predictive value (0.92; 95% CI 0.85, 0.96) and likelihood ratio of negative test (0.08; 95% CI 0.04, 0.16).Medical comorbidities can predict persistent hypoxia that requires unanticipated O2 supplementation to PAP therapy

2017 Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

178. A Diabetes Improvement in Medical Therapy Versus SADJB Study

Anastomosis Duodeno Jejunal Bypass With Sleeve Gastrectomy (SADJB-SG) Versus Intensive Medical Therapy (IMT) in the Treatment of Type 2 Diabetes Mellitus Among Asian Patients With BMI 23.5 - 30 kg/m2: A Clinical Trial Actual Study Start Date : April 1, 2017 Estimated Primary Completion Date : January 2019 Estimated Study Completion Date : April 2019 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: SADJB-SG (...) -regulated Device Product: No Keywords provided by Dr. Tikfu Gee, Universiti Putra Malaysia: Sleeve Gastrectomy Duodeno Jejunal Bypass Single Anastomosis Intensive Medical Therapy Diabetes Mellitus Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Overweight Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Body Weight Signs and Symptoms

2017 Clinical Trials

179. New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. Full Text available with Trip Pro

of opportunities to transform development approaches for new therapies for DKD. Platform trials along with appropriate biomarker-based enrichment strategies offer the possibility to foster drug development in a precision medicine era.© 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. (...) New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. Despite advances in pharmacotherapy, diabetic kidney disease (DKD) remains associated with a high burden of micro- and macrovascular complications often leading to premature mortality. New therapies are highly desirable to mitigate the burden of this disease. However, there are a number of barriers that hamper drug development in DKD. These include, amongst others, the lengthy and complex clinical

2018 obesity & metabolism

180. Medical genetics and genomic medicine in Nigeria Full Text available with Trip Pro

Medical genetics and genomic medicine in Nigeria 29871027 2018 10 17 2018 11 14 2324-9269 6 3 2018 05 Molecular genetics & genomic medicine Mol Genet Genomic Med Medical genetics and genomic medicine in Nigeria. 314-321 10.1002/mgg3.419 Adeyemo Adebowale A AA 0000-0002-3105-3231 National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland. Amodu Olukemi K OK Institute of Child Health, College of Medicine, University of Ibadan, Ibadan, Nigeria. Ekure Ekanem E EE (...) Department of Paediatrics, College of Medicine, University of Lagos, Lagos, Nigeria. Omotade Olayemi O OO Institute of Child Health, College of Medicine, University of Ibadan, Ibadan, Nigeria. eng News 2018 06 05 United States Mol Genet Genomic Med 101603758 2324-9269 IM Anemia, Sickle Cell diagnosis genetics Genetic Testing Genetics trends Genetics, Medical education Genomics education trends Humans Nigeria epidemiology Africa Nigeria genetic testing genetics genomics medical genetics 2018 04 23 2018 04

2018 Molecular Genetics & Genomic Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>